Posted On: 09/30/2014 8:58:28 PM
Post# of 273351
Biogen Idec Inc (BIIB) 330.81 $BIIB
Large-Cap Tech Names Hang Tough In Shaky Market
at Investor's Business Daily - Mon Sep 29, 5:32PM CDT
Large-cap stocks across a variety of sectors continue to hold up relatively well amid increasing higher-volume declines in the major averages and overall market uncertainty. Valeant Pharmaceuticals (VRX) is a new entrant to this week's list. The...
After Yesterday's Decline of 1.01%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Mon Sep 29, 4:13PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $326.85 to a high of $333.50. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $328.68 on volume of 765,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Sep 29, 4:13PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $326.85 to a high of $333.50. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $328.68 on volume of 765,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Research and Markets: North America Autoimmune Diagnostics Market Outlook 2019 Featuring Abbott Autoimmune, Bayer-Schering Pharma, Biogen Idec, Eli Lilly, GSK & Roche
Business Wire - Mon Sep 29, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrjsn8/north_america) has announced the addition of the "North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)" report to their offering.
North America Autoimmune Diagnostics Market Outlook 2019 Featuring Abbott Autoimmune, Bayer-Schering Pharma, Biogen Idec, Eli Lilly, GSK & Roche
M2 - Mon Sep 29, 11:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vj868g/north_america) has announced the addition of the "North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)" report to their offering. The term autoimmune disease refers to a varied group of illnesses that involve almost every human organ system. U.S being the largest market for autoimmune treatments holds 43% share in the global market, it will sustain its position and will hold 44% market share in 2016. A boost is expected for the U.S. autoimmune disease diagnostic testing market in 2014 due to the implementation of the Patient Protection and Affordable Care Act (PPACA). NIH estimates up to 23.5 million Americans have an autoimmune disease. And in fact, of the 50 million Americans living and coping with autoimmune disease (AD), more than 75 percent of them are women. Market is estimated to grow in this region because of the increased population of women suffering from autoimmune disease. North America autoimmune disease diagnostic market is segmented based on types i. e Localized autoimmune disease diagnostic and Systemic Autoimmune disease diagnostic segment, based on products( Drugs, Therapeutic and monitoring equipments, Diagnostic equipments), based on Service market( Consultation and Diagnosis, Therapy & Monitoring, Drug development and discovery), based on Technology( Bridge therapy, DMARD, Topical therapy, Phototherapy, Helminthes Therapy, Recombinant technology). Key Topics Covered: 1.Introduction 2.Executive Summary 3.Market Overview 4.Market Dynamics 5. North America Autoimmune Disease Market Diagnosis 6.MARKET SEGMENTATION 7. Competitive Landscape 8. Company profiles - Abbott Autoimmune Inc. - Bayer-Schering Pharmaceuticals - Biogen Idec - Eli Lilly - GlaxosmithKline - Roche For more information visit http://www.researchandmarkets.com/research/vj...th_america
These Companies Are Saving Money and Sticking You With a Tax Bill
Brian Orelli, The Motley Fool - Motley Fool - Sat Sep 27, 7:00AM CDT
Ireland, with its low corporate tax rate, has become a popular destination for U.S. companies. On the surface, tax inversions seem like a great deal for investors. A U.S. company buys a foreign company, moves its headquarters abroad, and inherits a...
'Fast Money' Recap: How to Trade After the Market's Drop
at The Street - Fri Sep 26, 4:00AM CDT
The trading panel likes the idea of buying Microsoft, Intel and other tech stocks if the market opens lower Friday
Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - Thu Sep 25, 5:55PM CDT
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....
Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Business Wire - Thu Sep 25, 4:34PM CDT
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report third quarter 2014 financial results on Wednesday, October 22, 2014, before the financial markets open.
Stocks Get Hit Hard; GoPro, Skechers Buck Weakness
at Investor's Business Daily - Thu Sep 25, 3:23PM CDT
Stocks suffered their biggest losses in nearly two months Thursday amid mixed data on weekly jobless claims and durable goods. Hurt by a near 4% drop in Apple (AAPL), the Nasdaq tumbled 1.9%. The S&P 500 lost 1.6%. Both indexes breached support at...
Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains
at Investor's Business Daily - Thu Sep 25, 12:31PM CDT
Buyers were in short supply in early-afternoon trading Thursday as another wave of institutional selling hit the Nasdaq. The tech-laden index slumped 1.8%, weighed down by weakness in Apple (AAPL). The Dow Jones industrial average and S&P 500 lost...
Apple Fuels Tech Sell-Off; Valeant Bucks The Trend
at Investor's Business Daily - Thu Sep 25, 10:34AM CDT
Major averages were sharply lower two hours into Thursday's session. The Nasdaq slumped 1.7% as Apple cast a pall on the tech sector. The Dow Jones industrial average and S&P 500 lost 1.2% each, and small caps took another hit as the Russell 2000...
Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 4.23%
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.23% Gain
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Skid; Vertex, Alexion Lead Biotech Rebound
at Investor's Business Daily - Wed Sep 24, 3:16PM CDT
The major averages rose Wednesday, erasing most of the week's losses, aided by dovish comments from a top Federal Reserve official. The Nasdaq rose 1%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. Volume was mixed, rising 6% on the...
Stocks Up In Afternoon; Hasbro Jumps On Disney Deal
at Investor's Business Daily - Wed Sep 24, 2:05PM CDT
The major averages were hitting fresh intraday highs in late afternoon trading Wednesday, spurred by dovish comments from a top Federal Reserve policymaker. The Nasdaq and the Dow Jones industrial average each added 0.9%, while the S&P 500 picked up...
Acorda To Buy Civitas, Gains Parkinson's Disease Drug
at Investor's Business Daily - Wed Sep 24, 12:27PM CDT
Acorda Therapeutics (ACOR) stock popped after the biotechnology company agreed to buy privately held Civitas Therapeutics for $525 million, gaining access to drugs in late development used to treat Parkinson's disease. Acorda obtained global rights...
Stocks Hold Solid Gains; CyberArk Soars In Debut
at Investor's Business Daily - Wed Sep 24, 12:20PM CDT
Major averages held solid gains in early afternoon trading Wednesday. The Nasdaq added 0.6%, the Dow Jones industrial average rose 0.5% and the S&P 500 picked up 0.4%. NYSE volume was tracking slightly higher than Wednesday. Nasdaq volume was...
Large-Cap Tech Names Hang Tough In Shaky Market
at Investor's Business Daily - Mon Sep 29, 5:32PM CDT
Large-cap stocks across a variety of sectors continue to hold up relatively well amid increasing higher-volume declines in the major averages and overall market uncertainty. Valeant Pharmaceuticals (VRX) is a new entrant to this week's list. The...
After Yesterday's Decline of 1.01%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Mon Sep 29, 4:13PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $326.85 to a high of $333.50. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $328.68 on volume of 765,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Sep 29, 4:13PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $326.85 to a high of $333.50. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $328.68 on volume of 765,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Research and Markets: North America Autoimmune Diagnostics Market Outlook 2019 Featuring Abbott Autoimmune, Bayer-Schering Pharma, Biogen Idec, Eli Lilly, GSK & Roche
Business Wire - Mon Sep 29, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrjsn8/north_america) has announced the addition of the "North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)" report to their offering.
North America Autoimmune Diagnostics Market Outlook 2019 Featuring Abbott Autoimmune, Bayer-Schering Pharma, Biogen Idec, Eli Lilly, GSK & Roche
M2 - Mon Sep 29, 11:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vj868g/north_america) has announced the addition of the "North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)" report to their offering. The term autoimmune disease refers to a varied group of illnesses that involve almost every human organ system. U.S being the largest market for autoimmune treatments holds 43% share in the global market, it will sustain its position and will hold 44% market share in 2016. A boost is expected for the U.S. autoimmune disease diagnostic testing market in 2014 due to the implementation of the Patient Protection and Affordable Care Act (PPACA). NIH estimates up to 23.5 million Americans have an autoimmune disease. And in fact, of the 50 million Americans living and coping with autoimmune disease (AD), more than 75 percent of them are women. Market is estimated to grow in this region because of the increased population of women suffering from autoimmune disease. North America autoimmune disease diagnostic market is segmented based on types i. e Localized autoimmune disease diagnostic and Systemic Autoimmune disease diagnostic segment, based on products( Drugs, Therapeutic and monitoring equipments, Diagnostic equipments), based on Service market( Consultation and Diagnosis, Therapy & Monitoring, Drug development and discovery), based on Technology( Bridge therapy, DMARD, Topical therapy, Phototherapy, Helminthes Therapy, Recombinant technology). Key Topics Covered: 1.Introduction 2.Executive Summary 3.Market Overview 4.Market Dynamics 5. North America Autoimmune Disease Market Diagnosis 6.MARKET SEGMENTATION 7. Competitive Landscape 8. Company profiles - Abbott Autoimmune Inc. - Bayer-Schering Pharmaceuticals - Biogen Idec - Eli Lilly - GlaxosmithKline - Roche For more information visit http://www.researchandmarkets.com/research/vj...th_america
These Companies Are Saving Money and Sticking You With a Tax Bill
Brian Orelli, The Motley Fool - Motley Fool - Sat Sep 27, 7:00AM CDT
Ireland, with its low corporate tax rate, has become a popular destination for U.S. companies. On the surface, tax inversions seem like a great deal for investors. A U.S. company buys a foreign company, moves its headquarters abroad, and inherits a...
'Fast Money' Recap: How to Trade After the Market's Drop
at The Street - Fri Sep 26, 4:00AM CDT
The trading panel likes the idea of buying Microsoft, Intel and other tech stocks if the market opens lower Friday
Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - Thu Sep 25, 5:55PM CDT
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....
Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Business Wire - Thu Sep 25, 4:34PM CDT
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report third quarter 2014 financial results on Wednesday, October 22, 2014, before the financial markets open.
Stocks Get Hit Hard; GoPro, Skechers Buck Weakness
at Investor's Business Daily - Thu Sep 25, 3:23PM CDT
Stocks suffered their biggest losses in nearly two months Thursday amid mixed data on weekly jobless claims and durable goods. Hurt by a near 4% drop in Apple (AAPL), the Nasdaq tumbled 1.9%. The S&P 500 lost 1.6%. Both indexes breached support at...
Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains
at Investor's Business Daily - Thu Sep 25, 12:31PM CDT
Buyers were in short supply in early-afternoon trading Thursday as another wave of institutional selling hit the Nasdaq. The tech-laden index slumped 1.8%, weighed down by weakness in Apple (AAPL). The Dow Jones industrial average and S&P 500 lost...
Apple Fuels Tech Sell-Off; Valeant Bucks The Trend
at Investor's Business Daily - Thu Sep 25, 10:34AM CDT
Major averages were sharply lower two hours into Thursday's session. The Nasdaq slumped 1.7% as Apple cast a pall on the tech sector. The Dow Jones industrial average and S&P 500 lost 1.2% each, and small caps took another hit as the Russell 2000...
Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 4.23%
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.23% Gain
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Skid; Vertex, Alexion Lead Biotech Rebound
at Investor's Business Daily - Wed Sep 24, 3:16PM CDT
The major averages rose Wednesday, erasing most of the week's losses, aided by dovish comments from a top Federal Reserve official. The Nasdaq rose 1%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. Volume was mixed, rising 6% on the...
Stocks Up In Afternoon; Hasbro Jumps On Disney Deal
at Investor's Business Daily - Wed Sep 24, 2:05PM CDT
The major averages were hitting fresh intraday highs in late afternoon trading Wednesday, spurred by dovish comments from a top Federal Reserve policymaker. The Nasdaq and the Dow Jones industrial average each added 0.9%, while the S&P 500 picked up...
Acorda To Buy Civitas, Gains Parkinson's Disease Drug
at Investor's Business Daily - Wed Sep 24, 12:27PM CDT
Acorda Therapeutics (ACOR) stock popped after the biotechnology company agreed to buy privately held Civitas Therapeutics for $525 million, gaining access to drugs in late development used to treat Parkinson's disease. Acorda obtained global rights...
Stocks Hold Solid Gains; CyberArk Soars In Debut
at Investor's Business Daily - Wed Sep 24, 12:20PM CDT
Major averages held solid gains in early afternoon trading Wednesday. The Nasdaq added 0.6%, the Dow Jones industrial average rose 0.5% and the S&P 500 picked up 0.4%. NYSE volume was tracking slightly higher than Wednesday. Nasdaq volume was...
(0)
(0)
